Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate

Fertility and Sterility

Volumn 75, Issue 6, 2001, Pages 1065-1079

  Utian, Wulf H ^a,f   Shoupe, Donna ^b   Bachmann, Gloria ^c   Pinkerton, Joanne V ^d   Pickar, James H ^e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e WYETH AYERST RESEARCH   (United States)

^f North American Menopause Society   (United States)

Author keywords

Conjugated equine estrogens (CEE); Hormone replacement therapy (HRT); Lower doses; Medroxyprogesterone acetate (MPA); Menopause; Postmenopausal women; Vaginal atrophy; Vaginal maturation index (VMI); Vasomotor symptoms; Women's HOPE study

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; FEMALE; FEMALE FERTILITY; HOT FLUSH; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL MATURATION; VAGINA ATROPHY; VAGINA BLEEDING; VAGINITIS; VASOMOTOR REFLEX;

ADULT; ANIMALS; ATROPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; FLUSHING; HORSES; HUMANS; INCIDENCE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PROGESTERONE CONGENERS; SEVERITY OF ILLNESS INDEX; VAGINA;

EID: 0034992739     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)01791-5     Document Type: Article

References (28)

1. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions Trial
2. Hot flashes: Phenomenology, quality of life, and search for treatment options
3. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee
4. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992
5. Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: Are there advantages?
6. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
7. Can we improve compliance with long-term HRT?
8. Women's concerns with hormone replacement therapy - Compliance issues
9. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy
10. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis
11. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women
12. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients
13. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
14. Personal perspective on low-dosage estrogen therapy for postmenopausal women
15. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms
16. Initial 17β-estradiol dose for treating vasomotor symptoms
17. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: Comparison with conjugated estrogens and placebo
18. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study
19. Ultra-low-dose transdermal estrogen therapy in postmenopausal urogenital estrogen deficiency - A placebo-controlled study
20. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate
21. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding
22. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism
23. Radioimmunoassay of plasma estrogens
24. The revised Bethesda system for reporting cervical/vaginal cytologic diagnoses: Report of the 1991 Bethesda workshop
25. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
26. The effects of progestins on vasomotor flushes
27. Hormones and sexual function
28. Postmenopausal symptomatology, maturation index, and plasma estrogen levels